Introduction
Renal cell carcinoma (RCC) remains one of the most common adult malignancies in the US (ranking seventh in men and eighth in women) with an estimated 58 240 new cases and 13 040 deaths in 2010 [1] . The overall incidence of kidney cancer is rising, at least in part due to increased use of cross-sectional imaging, such as CT scans and MRIs [2] . Despite increased detection and subsequent treatment, deaths from kidney cancer have not declined, largely because of the high mortality associated with metastatic disease [3] .
The systemic management of advanced and metastatic RCC (mRCC) has changed rapidly over the past 5 years with FDA approval of six targeted agents directed against aberrant vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. VEGF-pathway antagonists have largely replaced cytokine-based therapies as the first-line treatment for many patients with clear cell RCC, although high-dose IL-2 remains an appropriate option in selected patients [4, 5] . Given the multiple treatment options currently available, an oncologist may feel like the proverbial 'man with two watches', never sure of the time or which systemic therapy to offer. The development of targeted therapies for clear cell RCC and recent clinical and preclinical reports will be the major focus of this article; targeted strategies for patients with nonclear cell RCC have recently been reviewed elsewhere [6 ] . Whenever possible, trials are identified by their National Clinical Trial (NCT) number so the reader may easily find the study of interest on the National Institutes of Health's clinical trial registry website [7] .
Purpose of review
The article reviews the evolution of targeted therapies for clear cell renal cell carcinoma (RCC) and recent developments in the field. The vast majority of work in kidney cancer deals with clear cell RCC, which is the most common variant of this malignancy. The identification of loss of function of the von Hippel-Lindau protein as the basis for clear cell RCC, in addition to the well designed clinical trials that have ensued, provide an outstanding model for the development of mechanism-based targeted therapy in cancer.
Recent findings
The treatment of advanced and metastatic RCC continues to be a major challenge for uro-oncologists despite the approval of six targeted therapies over the past 5 years. This rapid growth in therapeutic options has brought much needed improvements in overall and progression-free survival, although durable complete responses are rare. However, the plurality of treatments also poses challenges in terms of selecting the best therapy for a given patient, designing trials with appropriate comparison arms and endpoints, identifying well tolerated and effective drug combinations or sequences, and determining the role of targeted therapies in the neoadjuvant and adjuvant settings. Summary Vascular endothelial growth factor and mammalian target of rapamycin-targeted therapies continue to play a critical role in the management of advanced and metastatic RCC. Ongoing research to identify novel agents continues to build upon the work done during the elucidation of the von Hippel-Lindau/clear cell RCC pathway. It is hoped that ongoing and planned studies will enable development of therapeutic regimens that will incorporate agents with improved toxicity and better efficacy as well as defining a role for a multidisciplinary approach to the management of advanced RCC. Study endpoints and quality of life
In order to chart a course forward, it is useful to reflect on the developments in the field of kidney cancer therapeutics over the past decade. In 2002, Motzer and colleagues [8] retrospectively analyzed data from six prospective trials that evaluated 463 patients with advanced RCC who had been treated with interferon-a (IFN-a) as first-line therapy and found that progression-free survival (PFS) and overall survival (OS) were 4.7 and 13 months, respectively. On the basis of this, they proposed that IFN-a should be considered the standard therapy to which new treatments are compared. Subsequently, sunitinib [9] , temsirolimus [10] , and bevacizumab [11, 12] were compared to IFN-a and found to be superior. In contrast, sorafenib [13] , everolimus [14] , and pazopanib [15] were found to be superior to placebo in their defining trials, although the intent of many of these protocols was to focus on patients who had already failed cytokine or anti-VEGF therapy (Table 1) .
Whereas IFN-a is no longer considered an appropriate comparator in randomized trials, no single agent has found universal favor as a suitable successor in first-line trials. In previously untreated patients, both sunitinib and temsirolimus (the latter in 'poor-risk' RCC) have led to improved OS in randomized phase III trials, supporting the notion that new therapies should be compared to one of these agents depending on the patient population under study. However, other agents, including sorafenib and pazopanib, are clearly active in RCC and constitute the comparator arm in several ongoing studies. It is hoped that head-to-head comparisons of these agents will eventually lead to the identification of a treatment standard that will then form the basis for the evaluation of new therapies.
The choice of an appropriate endpoint for evaluating the efficacy of targeted agents remains a matter of considerable debate. OS, PFS, and overall response rate (ORR) have each been used as the primary endpoint in pivotal trials of these agents (Table 1 ). An improvement in OS provides the most convincing evidence that a new therapy is superior to the existing standard of care. However, OS analyses in randomized trials may be confounded by the availability and widespread use of active agents in patients who progress on their assigned therapy. Final results from two randomized phase III studies comparing IFN-a with or without bevacizumab were recently reported and demonstrated a significant improvement in PFS but not OS in the bevacizumab arms [11, 12] . Whereas these results may represent a true discordance between PFS and OS, it is also possible that a survival benefit was obscured by the use of subsequent lines of treatment. In view of these concerns, PFS is likely to be the primary endpoint of choice in many future trials and is widely accepted as the basis for regulatory approval in RCC [16] .
In the absence of unequivocal survival benefits or direct head-to-head comparisons between the various drugs approved for mRCC, quality-of-life (QOL) assessments could help oncologists and their patients identify the therapies that offer a reasonable chance at prolonging life while favorably impacting on its quality. This is especially important considering that the side effects accompanying currently available targeted therapies are not likely to be offset by a durable complete response (CR), which, for example, may prompt some patients to accept the acute toxicity associated with high-dose interleukin-2 (IL-2) in exchange for the chance at cure. Since there is significant overlap in the mechanisms of action of individual drugs in a given class of targeted agents, their toxicity profiles are quite similar. However, newer agents currently in clinical trials such as tivozanib and axitinib, which are highly selective inhibitors of the VEGF receptors, appear to be associated with a better toxicity profile while retaining efficacy. Incorporation of QOL endpoints into trials comparing these agents with sunitinib or sorafenib should be considered and may guide treatment preferences even in the absence of differences in efficacy endpoints. Validated kidney cancer-specific QOL instruments are available, but they have not been universally adopted [17, 18] .
Molecular mechanisms underlying renal tumorigenesis
The majority of sporadic clear cell RCC tumors harbor mutations in the VHL tumor suppressor gene [19] (Fig. 1 ). [12] VEGF First-line IFN-a OS Pazopanib [15] VEGF-R First-line or Cytokine Failure Placebo PFS Sorafenib [13] VEGF-R Cytokine Failure Placebo OS Sunitinib [9] VEGF-R First-line IFN-a PFS Everolimus [14] mTOR VEGF-R Failure Placebo PFS Temsirolimus [10] mTOR First-line IFN-a OS OS, overall survival; PFS, progression-free survival; VEGF, vascular endothelial growth factor; VEGF-R, VEGF-receptor.
Loss of functional von Hippel-Lindau (VHL) protein (pVHL) results in the activation of proangiogenic and growth factor pathways via constitutive stabilization of the alpha subunits of a group of transcriptionally active proteins called the hypoxia-inducible factors (HIF) [20] . HIF plays a central role in renal tumorigenesis by acting as a transcription factor for genes that are involved in angiogenesis, tumor cell proliferation, cell survival and progression, metastatic spread, apoptosis and glucose metabolism [21] . The alpha subunits of HIF are also regulated at the translational level by growth factors through the phosphatidylinositol-3 kinase (PI3K)-AKT-mTOR signal transduction pathway [22] . Elucidation of the VHL/HIF pathway has led to the successful evaluation and regulatory approval of agents targeting the VEGF and mTOR axes. Whereas these therapies are clearly active in clear cell RCC, the vast majority of tumors eventually become refractory to therapy through a variety of different, as yet poorly understood, mechanisms. Novel agents as well as rational combinations are in development for the treatment of mRCC in an attempt to address these resistance mechanisms, and reduce severe side effects.
Update on clinical trials
The most recent addition to the growing list of FDAapproved agents with activity in RCC is pazopanib, a second-generation multitargeted tyrosine kinase inhibitor (TKI) that inhibits VEGF-R1/2/3, PDGF-Ra/b and ckit. Pazopanib was approved for use in metastatic RCC based on results from a recently published randomized phase III study in 435 patients with mRCC who had received no more than one prior cytokine therapy [15] . Patients were randomly assigned to receive either
The VHL gene is mutated in the majority of sporadic clear cell kidney cancer. As a result of mutation, the VHL protein cannot target and degrade hypoxiainducible factors (HIF) 1 a/2a. HIF over accumulates and causes increased transcription of downstream genes, such as vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) and transforming growth factor alpha (TGF-a). Current therapeutic approaches include antibodies, such as bevacizumab, that targets VEGF, tyrosine kinase inhibitors such as sunitinib, sorafenib, and pazopanib that target the VEGF and PDGF receptors and rapalogues such as temsirolimus and everolimus that target the mammalian target of rapamycin complex 1 (mTORC1). Future approaches could include agents that target HIF directly including histone deacetylase inhibitors (HDACi) and indirectly via inhibition of the mammalian target of rapamycin complex 2 (mTORC2).
pazopanib or placebo. Pazopanib was associated with a statistically significant improvement in PFS [median PFS 9.2 versus 4.2 months, hazard ratio 0.46, 95% confidence interval (CI) 0.34-0.62, P < 0.0001], as well as a significantly higher ORR (30 versus 3%, P < 0.0001). Final OS data from this trial are awaited. Pazopanib is now being compared with sunitinib as first-line therapy for advanced RCC in the phase III COMPARZ study (NCT00720941), and is being evaluated as second-line therapy in mRCC patients previously treated with VEGF-targeted therapy in a single arm phase II study (NCT00731211).
In addition to the plethora of VEGF-pathway antagonists already on the market, a number of novel agents directed against this pathway are currently undergoing evaluation in phase II-III trials. Some of these agents, with more selective activity against the VEGF receptors (such as tivozanib) represent an attempt to improve on the toxicity profile of currently available agents, whereas others are designed to provide additional activity against pathways thought to complement the VEGF axis in promoting angiogenesis and tumor growth. Axitinib is a newer generation, selective VEGF-R inhibitor with activity against all three VEGF receptors. In a phase II trial of patients with cytokine refractory RCC, axitinib demonstrated an ORR of 44% which included two CRs [23] . The median time to progression was 15.7 months and median OS 29.9 months. A second phase II study demonstrated activity of this agent in patients who had progressed on prior anti-VEGF-R therapy; in 62 patients who had received prior sorafenib, treatment with axitinib resulted in an ORR of 22.6% with a PFS of 7.4 months [24 ] . Axitinib is currently being evaluated in the phase III randomized AXIS trial (NCT00678392) versus sorafenib in patients who have failed one prior cytokine or TKI therapy.
Tivozanib is an oral pan-VEGF-R inhibitor that was recently studied in a phase II placebo-controlled randomized discontinuation trial in 272 RCC patients of whom 83% had clear cell RCC [25] . The trial highlighted the favorable toxicity profile associated with this agent, with fewer than 10% of patients developing Common Terminology Criteria for Adverse Events (CTCAE) grade 3/4 hypertension as well as a low incidence of palmar plantar syndrome, diarrhea, fatigue, stomatitis, and proteinuria. PFS was reported to be 364 days in the clear cell RCC group versus 220 days in patients with nonclear cell histology. The favorable toxicity profile of tivozanib might allow combination of this agent with mTOR inhibitors in clinically meaningful doses. Indeed, a phase I-II trial of this agent in combination with temsirolimus is currently ongoing. Tivozanib is also being evaluated in the phase III TIVO-1 trial (NCT01030783) versus sorafenib in previously untreated patients with advanced RCC.
Other agents with new and distinct antiangiogenic profiles undergoing evaluation in patients with advanced RCC include regorafenib and dovitinib. Regorafenib inhibits both VEGFR-2 and TIE2 TK and may have advantages over inhibition of the VEGF axis alone. Data from a phase II trial of regorafenib in patients with mRCC were presented at the joint 15th ECCO Congress in 2009 and demonstrated a 31% PR and 50% stable disease rate. Dovitinib, an orally available TKI, has activity against VEGF-R1/2/3, PDGF-R, c-kit, FLT3 and additionally fibroblast growth factor (FGF) receptor 1, 2 and 3. Activating mutations in FGF-Rs or their ligands have been detected in a number of tumor types including RCC, and signaling via this pathway has been suggested as a resistance mechanism to VEGF-R inhibition [26] . Dovitinib is currently being investigated in phase II studies of mRCC with some preliminary reports of partial responses (PR) and stable disease [27] . Further elucidation of mechanisms resulting in resistance to VEGF pathway antagonists, and the development of strategies directed against these mechanisms, are areas of active investigation.
In addition to the VEGF-R axis, a number of other molecules such as AKT are being pursued as possible therapeutic targets. Perifosene targets the pleckstrin homology domain of AKT, thereby preventing its translocation to the plasma membrane and subsequent activation by PDK1 and mTORC2 complexes. In two phase II studies in patients with advanced RCC who had progressed on prior VEGF-R TKI and/or mTOR inhibitor, perifosene led to disease stabilization as well as some objective responses with manageable toxicities [28, 29] .
Combination strategies designed to provide maximal blockade of key components of the HIF pathway have typically involved attempts to exploit potential synergy between inhibitors of the VEGF and mTOR pathways. The majority of these combinations have been associated with significant toxicity, precluding their evaluation in phase II-III trials. An exception is the combination of bevacizumab and everolimus, a reasonably well tolerated regimen which was evaluated in a single-arm phase II trial [30 ] . The combination was active in both treatment-naïve patients (ORR 30%, median PFS 9.1 months) and in those who had progressed on sunitinib or sorafenib (ORR 23%, median PFS 7.1 months). Everolimus, with or without bevacizumab, is currently being studied in a randomized placebo controlled trial in patients refractory to first-line VEGF-R inhibitors under the aegis of Cancer and Leukemia Group B (CALGB) (NCT01198158).
The prognostic criteria identified by Motzer and colleagues [8] from Memorial-Sloan Kettering Cancer Center in patients with mRCC undergoing therapy with cytokines have formed the basis for risk-stratification in both clinical practice and experimental trials. These criteria were partially validated and extended (with the addition of elevated neutrophil and platelet counts) by Heng and colleagues [31 ] in a group of 645 patients who had received a variety of VEGF pathway antagonists. Efforts at external validation of these criteria using an independent data set are ongoing, and may help refine prognostication in patients receiving targeted agents.
Preclinical developments
Significant progress has been made in drug development for clear cell RCC during the past decade as a result of our ability to better characterize the biochemical consequences of VHL inactivation. Further insights into mTOR biology and HIF regulation have led to the development of strategies designed to optimize inhibition of this pathway. It is now known that mTOR exists in two biochemically and functionally distinct complexes, mTORC1 and mTORC2. Recent evidence suggests that HIF-2a, a HIF isoform believed to play a significant role in mediating clear cell renal tumorigenesis, is regulated by mTORC2 rather than mTORC1 [32 ] . Conventional mTOR inhibitors, such as temsirolimus and everolimus, inhibit mTORC1 but not mTORC2. In addition, these agents initiate a negative feedback loop leading to a paradoxical increase in mTORC2 activity and AKT activation. Several new PI3K/mTORC1/2 complex inhibitors are currently in development in a bid to overcome the limitations of selective mTORC1 inhibition. In contrast to rapalogues, which primarily down-regulate HIF-1a, these dual mTOR inhibitors induce profound reduction of both HIF-1a and HIF-2a levels and are associated with more potent antitumor activity in animal xenograft models [33 ] . XL765 (NCT00485719), AZD8055 (NCT00973076) and BEZ235 (NCT01195376) are a few of the dual mTOR inhibitors that are currently in phase I trials in advanced solid malignancies.
Recent preclinical studies with histone deacetylase (HDAC) inhibitors have shown antineoplastic effects on RCC cells. These agents are well known to affect gene expression through the hyperacetylation of histones and have been reported to reduce HIF-1a and VEGF transcription [34] . In addition, HDAC inhibitors have been shown to promote proteosomal degradation of HIF-1a in an oxygen/ pVHL-independent manner [35] . Clinically, a number of these agents are in human trials. Vorinostat has been tested as monotherapy and demonstrated prolonged disease stabilization in RCC [36] . Additional phase II trials are underway with vorinostat as monotherapy (NCT00278395) and as combination therapy with bevacizumab (NCT00324870) or ridaforolimus (NCT01169532).
Although much of the excitement surrounding drug development for RCC has focused on signal transduction inhibitors, continued work with immunomodulation to reproduce the elusive CRs and long-term remissions obtained with IL-2, albeit in a small proportion of patients, continues. Therapeutic interest has arisen in IL-21, a member of the IL-2 family. This cytokine has demonstrated evidence of antitumor activity superior to IL-2 in an animal model of RCC [37] . Recombinant IL-21 was well tolerated in early studies, and demonstrated a stable disease rate of 89% in a phase I trial in patients with mRCC or melanoma. Four patients with RCC had a PR [38] . Combination therapy with sorafenib is underway in a phase I-II study in patients with metastatic clear cell RCC (NCT00389285).
Neoadjuvant therapy and the role of cytoreductive nephrectomy in the era of targeted therapy
Whereas agents targeting the VEGF and mTOR pathways have an established role in the management of mRCC, we are yet to understand how these agents can be integrated with surgical approaches to maximize clinical benefit. Several studies have explored the feasibility and utility of VEGF pathway inhibitors in the neoadjuvant setting. The theoretical advantages of administering systemic therapy before surgery are many and include assessment of primary tumor response, tumor downstaging, and decreasing circulating tumor cells [39, 40] . Early reports suggest that these therapies lead to modest regression of primary tumors, with sufficient downstaging in some patients to permit surgical extirpation of previously unresectable tumors [41 ,42] . Although studies have demonstrated the general tolerability of targeted agents, there are still limited data on the safety of surgical resection following treatment with these agents, and several studies have shown increased perioperative complications after treatment with sunitinib, sorafenib, or bevacizumab [43, 44] .
The concept of neoadjuvant therapy is attractive on many fronts; however, the approach must be validated in randomized clinical trials before being widely adopted. The role of cytoreductive nephrectomy in patients with metastatic disease receiving VEGF-targeted agents is another area that deserves further study. The current paradigm of debulking nephrectomy is based on data generated in the era of cytokine therapy, but is commonly used as a prelude to targeted therapy.
Several ongoing studies are designed to clarify these critical issues. The SURTIME study (NCT01099423) from the EORTC is a phase III trial of 458 patients with their primary tumor in situ and synchronous mRCC. Patients are randomized to sunitinib followed by nephrectomy or nephrectomy followed by sunitinib with PFS as the primary endpoint. A second study, CARMENA (NCT00930033), is a randomized phase III trial comparing sunitinib therapy alone versus cytoreductive nephrectomy followed by sunitinib therapy.
Adjuvant therapy for clear cell renal cell carcinoma
A proportion of patients with seemingly organ confined and locally advanced RCC are at risk for progression after surgical resection. Adjuvant therapy has been used in the treatment of several malignancies with favorable results; however, cytokine treatment regimens, radiation therapy, and thalidomide have failed to improve outcomes in RCC when used in the adjuvant setting [45] [46] [47] . Several randomized, phase III trials are currently evaluating the impact of VEGF pathway antagonists on PFS, OS and safety/tolerability in the adjuvant setting. The S-TRAC trial (NCT00375674) is a randomized, twoarm, double-blind trial started in 2007. Patients at high risk of recurrence based on the University of California Los Angeles Integrated Staging System (UISS) are randomized to receive sunitinib versus placebo for 12 months; accrual is ongoing. The ASSURE trial (NCT00326898) is a large, double-blind trial with an accrual goal of close to 2000 patients. Patients with pT1b, G3-4, pT2-T4, or any T with node positive RCC are randomized after nephrectomy to receive 1 year of sunitinib, sorafenib, or placebo. The primary endpoint is DFS and the anticipated completion date for data analysis is 2016. The last ongoing trial is the SORCE trial (NCT00492258) which is a three-arm phase III study that randomizes patients at high or intermediate risk of relapse using the Leibovich score to placebo for 3 years versus placebo for 2 years combined with sorafenib for 1 year versus sorafenib for 3 years. The trial's estimated primary completion date is in late 2012. The results of these trials are eagerly awaited to determine the role of targeted therapy in the adjuvant setting.
Conclusion
Targeted therapies continue to be an integral component in the treatment of advanced and metastatic RCC. Novel agents and new combinations of existing treatments are being tested in trials throughout the world. Despite the successes of targeted therapies, much work remains to be done [48] .
The knowledge that has been gained treating patients with clear cell RCC must also be translated into the nonclear cell histologies, which have traditionally been excluded from large kidney cancer trials [6 ] . Additional work to identify predictors of tumor sensitivity or resistance to therapy, and biomarkers for monitoring response to treatment, are urgently needed [49] . The role of neoadjuvant and adjuvant systemic therapy must also be defined. Urologists and oncologists must continue to support kidney cancer clinical trials at the local, regional, and national levels in order to answer these and other pressing questions related to the management of advanced kidney cancer.
